PRESS RELEASE : EVOTEC PRESENTS GROWTH DRIVERS OF 'AUTOBAHN TO CURES' AT CAPITAL MARKETS DAY

 
 DGAP-News: Evotec SE / Key word(s): Miscellaneous 
EVOTEC PRESENTS GROWTH DRIVERS OF 'AUTOBAHN TO CURES' AT CAPITAL MARKETS DAY 
 
2020-11-19 / 07:30 
The issuer is solely responsible for the content of this announcement. 
 
? _CO-OWNED PIPELINE: EVOLUTION FROM DISCOVERY INTO CLINICAL-STAGE 
PROJECTS_ 
 
? _PRECISION MEDICINE DEVELOPING MEDICINES OF THE FUTURE WITH NOVEL AI & 
ML PREDICTION TOOLS_ 
 
? _MULTIMODALITY PLATFORMS DRIVING R&D PROJECTS TOWARDS HIGHER EFFICIENCY 
AND BROADER ACCESS AT HIGH SPEED_ 
 
*Hamburg, Germany, 19 November 2020:* 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) 
today presents the progress made in accelerating its co-owned pipeline and 
its global infrastructure "The R&D Autobahn to Cures". The Company is 
hosting a virtual Capital Markets Day for investors and interested 
stakeholders. 
 
Evotec pursues a unique strategy to become the globally leading platform 
company for the modality-agnostic development of innovative first-in-class 
and best-in-class therapeutic approaches resulting in a very large co-owned 
pipeline. 
 
The Company will provide a detailed business overview focusing on 
 
? building long-term value on its co-owned pipeline 
 
? highly efficient and effective platforms as future tools for data 
generation and analysis (e.g. PanOmics and PanHunter) 
 
? iPSC as a leading new paradigm for early disease relevance and 
data-driven precision medicine 
 
? operational excellence, from the industry-leading "R&D Autobahn to 
Cures" over artificial intelligence and machine learning tools and 
applications to the facility of the future in Biologics 
 
*Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: *"I am 
pleased to present together with my Team selected highlights of the 
scientific potential of all our platforms. Precision medicine and better 
access to more affordable drugs will define the road into the future of this 
industry. Evotec will be an essential part of the infrastructure for all 
relevant technologies and modalities." 
 
*About the virtual Capital Markets Day* 
Evotec will host its virtual Capital Markets Day on 19 November 2020, 
starting at 8.30 am EST (2.30 pm CET, 1.30 pm GMT). The meeting will take 
place via a live webcast and a replay of the recorded webcast will be 
available on www.evotec.com [1]. 
 
ABOUT EVOTEC SE 
Evotec is a drug discovery alliance and development partnership company 
focused on rapidly progressing innovative product approaches with leading 
pharmaceutical and biotechnology companies, academics, patient advocacy 
groups and venture capitalists. We operate worldwide and our more than 3,400 
employees provide the highest quality stand-alone and integrated drug 
discovery and development solutions. We cover all activities from 
target-to-clinic to meet the industry's need for innovation and efficiency 
in drug discovery and development (EVT Execute). The Company has established 
a unique position by assembling top-class scientific experts and integrating 
state-of-the-art technologies as well as substantial experience and 
expertise in key therapeutic areas including neuronal diseases, diabetes and 
complications of diabetes, pain and inflammation, oncology, infectious 
diseases, respiratory diseases, fibrosis, rare diseases and women's health. 
On this basis, Evotec has built a broad and deep pipeline of more than 100 
co-owned product opportunities at clinical, pre-clinical and discovery 
stages (EVT Innovate). Evotec has established multiple long-term alliances 
with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, 
CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For 
additional information please go to www.evotec.com [1] _and follow us on 
Twitter_ @Evotec [2]_. 
 
FORWARD-LOOKING STATEMENTS_ 
Information set forth in this press release contains forward-looking 
statements, which involve a number of risks and uncertainties. The 
forward-looking statements contained herein represent the judgement of 
Evotec as of the date of this press release. Such forward-looking statements 
are neither promises nor guarantees, but are subject to a variety of risks 
and uncertainties, many of which are beyond our control, and which could 
cause actual results to differ materially from those contemplated in these 
forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such 
statements to reflect any change in our expectations or any change in 
events, conditions or circumstances on which any such statement is based. 
 
Media Contact Evotec SE: 
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, 
Phone: [phone], [e-mail] 
 
IR Contact Evotec SE: 
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: 
+49.(0)40.56081-775, [e-mail] 
 
2020-11-19 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     Evotec SE 
             Manfred Eigen Campus / Essener Bogen 7 
             22419 Hamburg 
             Germany 
Phone:       [phone] 
Fax:         [phone] 
E-mail:      [e-mail] 
Internet:    www.evotec.com 
ISIN:        DE0005664809 
WKN:         566480 
Indices:     MDAX, TecDAX 
Listed:      Regulated Market in Berlin, Frankfurt (Prime Standard); 
             Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, 
             Munich, Stuttgart, Tradegate Exchange 
EQS News ID: 1149278 
 
End of News DGAP News Service 
 
1149278 2020-11-19 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=d9f30c4aeb65d3276d5bd878be7dc75c&application_id=1149278&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b578791509083b40bb44fb801a96a7b5&application_id=1149278&site_id=vwd&application_name=news

(END) Dow Jones Newswires

November 19, 2020 01:30 ET (06:30 GMT)